WOODCLIFF LAKE, N.J., Sept. 18 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL - News) today announced that the United States Court of Appeals for the Second Circuit has denied the plaintiffs’ petitions for rehearing and rehearing en banc in the Tamoxifen Citrate antitrust lawsuits. The denial of the petitions follows the Court’s November 2005 affirmation of the dismissal of the cases for failure to state a viable antitrust claim. The Court’s ruling ends the litigation before the Second Circuit.
